CallonDoc

What the company does

CallonDoc, written Call-On-Doc on most of its own pages, is a direct-to-consumer online medical service built around short, text-based visits with a flat fee. A patient picks a condition, completes an intake form that the company says takes five to ten minutes, and a licensed provider reviews it and, where appropriate, sends a prescription to the patient’s chosen pharmacy. The company says visits can be submitted at any hour, that no appointment is needed, and that prescriptions are typically processed within two hours during business hours.

The service lists more than 150 conditions across urgent care, sexually transmitted infections, women’s health, men’s health, mental health, primary care, pediatrics, dermatology, and weight loss, with lab-test and imaging orders, prescription refills, at-home test kits, a prescription discount card, a skincare product line, and Spanish-language service alongside. A separate business-to-business program, CallonDoc Plus, sells co-branded telehealth to partner organizations.

History and ownership

The company’s January 2022 press release says CallonDoc was launched in January 2018 by a Dallas-based husband-and-wife team of doctors; the Better Business Bureau records a business start date of February 27, 2018; the company’s FAQ says the platform has been operating since 2017. This profile uses 2018, the launch year the company itself announced, and notes the earlier date. TJ Oshun is identified as the founder in a December 2024 podcast interview and as chairperson and CEO in the BBB profile, which describes the business as a corporation in Dallas, Texas. The Terms of Use say the owner of the site and app is based in Texas.

Three spellings of the corporate name appear in public records. The Terms of Use say they are entered into between the user and Call-On-Doc.Com, Inc., which they say operates the site, with a Dallas, Texas mailing address. The site footer reads “© 2026 Call-On-Doc, Inc.” and says Call-On-Doc is a registered trademark of Call-On-Doc, Inc., and the caption of a 2026 class action names Call-On-Doc, Inc. as the defendant. The BBB profile and the Apple App Store seller listing use CallonDoc.com Inc. Whether these are one entity under different spellings or related entities is not stated publicly, and none of these records establishes which entity engages the clinicians. No investors, funding, acquisitions, or revenue are disclosed.

Services and clinical model

The consumer condition pages observed on September 7, 2026 advertise text consultations with no appointment and results in as little as 15 minutes, and the app listing advertises expedited visits in 30 minutes or less. The company’s January 2022 release said patients could choose video, phone, or text consultation, and its partner-platform page markets phone visits, video visits, messaging, and asynchronous visits for partner deployments; whether consumer visits currently offer video or phone was not determined from the public pages, so this profile classifies the consumer service as asynchronous on the strength of the current consumer pages only. The FAQ describes the providers as licensed, board-certified doctors and nurse practitioners who are licensed in the state where the patient resides, and says that if a condition needs in-person examination or cannot be treated by telehealth the consultation fee is refunded and a referral offered. The company says it does not treat severely ill or medically unstable patients, and its anxiety page states that it does not prescribe controlled substances. The Terms of Use do not name a medical group or describe how the providers are engaged.

Prescriptions go to the patient’s pharmacy; the FAQ names CVS, Walgreens, and Walmart as examples and says online pharmacies with home delivery are available for certain medications, with some home-delivery plans that include the medication cost for weight loss, erectile dysfunction, and mental health. The company says a patient whose prescription has not resolved the condition can get a follow-up review or a diagnostic-test recommendation at no extra cost within ten days. Its 2022 release introduced at-home test kits priced $35 to $50 with free delivery. Membership plans add 24/7 access to a nurse line and what the company calls an AI Doctor; the company does not describe what that tool does.

Availability

The site’s state-coverage list names all 50 states and the District of Columbia with no per-service exclusions, and the FAQ says the service is available to anyone in the United States. Inside Telehealth has not tested intake in any state and has not verified provider licensure. Checked September 7, 2026.

Pricing and insurance

Consultations are cash-pay and, per the FAQ, are not billed to insurance; the visit fee covers the provider’s review and any prescription, and the medication is paid for separately at the pharmacy, where the patient may use insurance or the company’s discount card. Per-visit prices are displayed on each condition page. On September 7, 2026 they were $39.99 for sinus infection, chlamydia, birth control, pediatric, and Paxlovid visits, $49.99 for acne, and $75.00 for anxiety. No price is displayed on the public weight-loss page as observed; Inside Telehealth did not start a visit to see whether one appears later. The chlamydia page advertises 50 percent off expedited partner treatment.

The Subscribe & Save page sells two memberships: an Advantage Plan at $24.99 per month or $59.99 per quarter with two visits per month, one included dependent on the monthly plan or two on the quarterly plan, and 10 percent off further visits, and a Premium Plan at $49.99 per month or $129.99 per quarter with five visits per month, two included dependents on the monthly plan or three on the quarterly plan, and 15 percent off further visits. The company markets these as visits “as low as $12”; the page does not explain the basis of that figure. Dividing each plan’s price by its included visits gives $12.50 and $10.00 a visit on the monthly plans and $10.00 and $8.67 on the quarterly plans if every included visit is used, and more per visit if not. Plans can be paused or canceled from the account dashboard, and the same page says a program called Compassionate Care is paused.

The refund policy in the FAQ says services are non-refundable once a prescription has been transmitted or a treatment plan completed, that a visit is fully refunded if the company cannot treat the condition, that a patient can cancel for a refund before a provider has reviewed the case, and that no refund is issued because insurance declines a medication or the pharmacy price is higher than expected. A referral program credits $10 to each party after a new user’s first visit.

Regulatory, legal, and privacy context

Call-On-Doc, Inc. was the defendant in Lucas v. Call-On-Doc, Inc., Case No. 2026LA000403, in the Circuit Court of Will County, Illinois, a class action over the use of third-party tracking pixels on its web pages, alleged to violate California privacy law. The court granted final approval on August 31, 2026 and dismissed the action with prejudice; the order records no determination or admission of wrongdoing, and the company denies wrongdoing. ClassAction.org reported the April 2026 filing and preliminary approval on May 19, 2026. The $1.8 million is a claims-made maximum covering administration, fees and incentive awards, not a guaranteed payout.

The company’s privacy policy was last updated October 22, 2025 and describes disclosures to marketing vendors and a Do Not Sell or Share option. Its Terms of Use include binding individual arbitration and a class action waiver under Texas law. The BBB profile showed 288 complaints filed against the business, a B rating, and BBB accreditation since March 9, 2026 when read on September 7, 2026; the BBB says its profiles generally cover the prior three years, and a complaint count is not a rate or a regulator’s finding. No FDA, FTC, or state medical board action naming the company was found in a web search on that date.

Scale and operating context

The company discloses no revenue, patient, or provider counts in a form that can be checked. Its own 2022 release claimed more than 2.7 million treatments fulfilled and more than 89,000 five-star reviews; its app listing claims more than 260,000 five-star reviews, and its FAQ says it is trusted by millions of patients. On September 7, 2026 the Google Play listing showed more than 100,000 installs and a 4.9 rating from about 6,500 reviews, and the App Store listing a 4.9 rating from about 26,000 ratings. The “Mid-sized” size tier on this profile is a provisional editorial judgment from these company-reported volumes; Inside Telehealth has no revenue or headcount figures. The partner program prices co-branded telehealth at a $2,000 setup fee plus $500 per month for a starter plan and a $7,500 setup fee with tiered monthly fees from $500 to $2,500 for a business plan.

Evidence and limitations

This record establishes the company’s identity, founding, ownership as far as it is public, service model, availability claim, price points, refund and insurance rules, and one dated legal matter, from the company’s own pages, its app listings, a company press release, a court-authorized settlement site, a legal-news report, a podcast interview, and the Better Business Bureau. It makes no clinical claims and does not evaluate the care provided. Prices were read from public pages on one date and not tested through checkout; weight-loss pricing was not visible without starting a visit; the company’s review and patient counts are its own claims. The three name variants for the corporate entity are recorded as an open question. No Internet Archive capture from the observation date was recorded for the cited pages.